Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
Pemetrexed is an FDA-approved treatment for advanced lung cancer but the response rate is
still very low. Bortezomib is currently approved to treat myeloma in patients who have
already been treated. Currently, multiple studies are actively investigating how well
bortezomib works with other drugs. This study is testing how much bortezomib can be given to
advanced lung cancer patients who have already received one treatment. This study will also
see how well bortezomib and pemetrexed work together to treat lung cancer patients.